Peter Kotsonis, PhD

Executive Director
Office of Strategic Alliances
+ 1 415 323-3108

Peter is PhD-neuroscientist and drug hunter with 14 years in the pharmaceutical industry, project leader and co-inventor of Ronopterin (VAS203) for traumatic brain injury currently in Phase III clinical development. Peter has experience in academic start-ups (VasoPharm Biotech GmbH) and pharma settings (Novartis Ag and Dainippon Sumitomo Pharma Co, Ltd). He joined UCSF in 2013, and his responsibilities include driving new partner opportunities, developing novel partnering models, and programmatic support using alliance management “best practices” comparable to industry. 

Publications: 

Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.

Journal of medicinal chemistry

Culshaw AJ, Bevan S, Christiansen M, Copp P, Davis A, Davis C, Dyson A, Dziadulewicz EK, Edwards L, Eggelte H, Fox A, Gentry C, Groarke A, Hallett A, Hart TW, Hughes GA, Knights S, Kotsonis P, Lee W, Lyothier I, McBryde A, McIntyre P, Paloumbis G, Panesar M, Patel S, Seiler MP, Yaqoob M, Zimmermann K

Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases.

Journal of medicinal chemistry

Matter H, Kumar HS, Fedorov R, Frey A, Kotsonis P, Hartmann E, Fröhlich LG, Reif A, Pfleiderer W, Scheurer P, Ghosh DK, Schlichting I, Schmidt HH

Vanilloid receptor TRPV1, sensory C-fibers, and vascular autoregulation: a novel mechanism involved in myogenic constriction.

Circulation research

Scotland RS, Chauhan S, Davis C, De Felipe C, Hunt S, Kabir J, Kotsonis P, Oh U, Ahluwalia A

N-Formyl peptide receptor subtypes in human neutrophils activate L-plastin phosphorylation through different signal transduction intermediates.

The Biochemical journal

Paclet MH, Davis C, Kotsonis P, Godovac-Zimmermann J, Segal AW, Dekker LV

Cloning and functional characterization of the guinea pig vanilloid receptor 1.

Neuropharmacology

Savidge J, Davis C, Shah K, Colley S, Phillips E, Ranasinghe S, Winter J, Kotsonis P, Rang H, McIntyre P

Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors.

Journal of medicinal chemistry

Matter H, Kotsonis P, Klingler O, Strobel H, Fröhlich LG, Frey A, Pfleiderer W, Schmidt HH

Life Sci

Modulation of acetylcholine release from mouse cortex by protein kinase C: dependence on stimulation intensity.

Iannazzo L, Kotsonis P, Majewski H.

Eur J Pharmacol

Structural determinants of phorbol ester binding in synaptosomes: pharmacokinetics and pharmacodynamics.

Murphy TV, Prountzos C, Kotsonis P, Iannazzo L, Majewski H.

Br J Pharmacol

The structural requirements for phorbol esters to enhance serotonin and acetylcholine release from rat brain cortex.

Iannazzo L, Kotsonis P, Majewski H.